Cannabinoid administration modulates both dopaminergic and glutamatergic neurotransmission. The present study examines the effects of high and low dose WIN55,212-2, a CB 1 receptor agonist, on extracellular dopamine and glutamate release in vivo via brain microdialysis in the nucleus accumbens (NAc), striatum and prefrontal cortex (PFC) in parallel to its effects on locomotor activity. WIN55,212-2 increased extracellular dopamine in the NAc (1 mg/kg i.p.), striatum (0.1 and 1 mg/kg i.p.) and PFC (1 mg/kg i.p.). Glutamate release was also elevated by WIN55,212-2 in the PFC (1 mg/kg i.p.) whereas in the NAc (0.1 and 1 mg/kg i.p.) and striatum, it was reduced (1 mg/kg i.p.). WIN55,212-2 administration produced hyperlocomotion at the lower dose (0.1 mg/kg i.p.) and hypolocomotion at the higher dose (1 mg/kg i.p.). Co-administration with the CB 1 antagonist, SR-141716A (0.03 mg/kg i.p.), prevented the above effects. According to the present results, WIN55,212-2 affected locomotor activity biphasically while exerting converging effects on dopamine activity but diverging effects on glutamate release between cortical and subcortical regions, especially at the higher dose. These findings emphasize the involvement of the CB 1 receptor in the simultaneous modulation of dopaminergic and glutamatergic neurotransmission in brain regions involved in reward and locomotion and suggest possible underlying mechanisms of acute cannabinoid exposure and its psychoactive and behavioural manifestations.
Introduction
CB 1 receptors are expressed abundantly throughout the brain, assisting their role in the modulation of neurotransmission. The endocannabinoid system (ECS) pre-synaptically regulates both excitatory and inhibitory neurotransmission, implicating it in many neuronal processes such as locomotion, reward and cognition. Two main neurotransmitters involved in these functions and modulated by the ECS are dopamine and glutamate.
Cannabinoids have been demonstrated to increase dopamine release in the prefrontal cortex (PFC ; Pistis et al. 2002) . In vivo studies have demonstrated increases in extracellular dopamine release in the nucleus accumbens (NAc) after D 9 -tetrahydrocannabinol (D 9 -THC) administration (Chen et al. 1990b (Chen et al. , 1991 Ng Cheong Ton et al. 1988 ; Tanda et al. 1997) . In addition, dose-dependent increases in dopamine efflux have been observed in the striatum and the PFC (Chen et al. 1990a ; Malone & Taylor, 1999) . In this regard, neurochemical studies assessing the release of dopamine following cannabinoid exposure fundamentally support a correlation between cannabinoid-induced behavioural effects and dopamine alterations in distinct brain regions (Polissidis et al. , 2010 .
Interestingly, CB 1 receptors do not appear to be located at dopaminergic terminals in these main regions of dopamine innervation ; thus, the effects of cannabinoids on dopamine transmission are mainly indirect and modulated via other neurotransmitters ' function such as glutamate (Fernandez-Ruiz et al. 2010) . Independent studies have shown that D 9 -THC and other cannabinoid agonists, such as WIN55,212-2, induce a decrease in glutamatergic neurotransmission in the hippocampus, striatum and NAc (Adermark et al. 2009 ; Cannizzaro et al. 2006 ; Fujiwara & Egashira, 2004 ; Pintor et al. 2006 ; Sano et al. 2008) . On the other hand, additional studies have shown CB 1 receptor activation with D 9 -THC or WIN55,212-2 increases extracellular glutamate levels in the cortex (Ferraro et al. 2001 ; Pistis et al. 2002) . These cannabinoid-induced actions on glutamatergic neurotransmission in multiple brain regions go hand in hand with their effects on motor activity, reward function, cognition and neuroprotection or neurotoxicity.
Consistently, pharmacological treatments with CB 1 agonists exert biphasic effects, especially concerning motor activity, with low doses inducing motor activation and high doses producing suppressed motor activity or catalepsy (Drews et al. 2005 ; Polissidis et al. 2010 ; Rodvelt et al. 2007 ; Sanudo-Pena et al. 2000 ; Sulcova et al. 1998) . Interestingly, no study has focused on the simultaneous in vivo estimation of glutamate and dopamine in distinct brain regions after specific doses of cannabinoids, which produce excitation or suppression of motor activity, respectively.
In this context and based on the key role of dopamine and glutamate in basal ganglia and corticolimbic processes, we first sought to investigate the effects of systemic administration of low and high dose WIN55,212-2 on motor activity patterns as well as characterize the profile of in vivo dopamine and glutamate release in the striatum, NAc and PFC accompanying these observed motor effects We then examined the ability of SR-141716A, a CB 1 receptor antagonist, to reverse the WIN55,212-2-induced CB 1 receptor-mediated behavioural and neurochemical alterations.
Method

Animals
Male Sprague-Dawley rats (purchased from the Pasteur Institute, Greece), aged 80-90 d, weighing 250-300 g, were used for all experiments. Animals were group-housed with food and water available ad libitum under a controlled 12-h light/dark cycle (lights on 07:00 hours) and temperature (21+1 xC).
All experiments were performed in accordance with the EU directive guidelines for care and use of experimental animals (86/609/EEC ; 27/01/1992, No. 116) .
Behavioural studies : non-habituated and habituated motor activity All animals were accustomed to the experimental room for 40 min prior to the experiment. Motor behaviour was recorded with computerized activity monitoring (ENV515, Activity Monitor, version 5 ; Med Associates Inc., USA) in a transparent open activity box (40r40r40 cm). Vertical counts represented vertical activity and ambulatory distance was used as index of horizontal activity .
A subset (n=33) of rats was used for the nonhabituated motor activity experiments. Rats were injected i.p. with one of four treatments : vehicle/ vehicle, vehicle/WIN55,212-2 (1 mg/kg), SR-141716A (0.03 mg/kg)/vehicle or SR-141716A/WIN55,212-2 in their home cages, with a 10 min interval between injections. Ten minutes following the last injection, the rats were placed in the testing apparatus and motor activity was recorded for 1 h.
Another subset of rats (n=33) was used for habituated motor activity experiments. The rats were habituated for 20 min to the activity box and then injected i.p. with vehicle/vehicle, vehicle/WIN55,212-2 (0.1 mg/kg), SR-141716A (0.03 mg/kg)/vehicle and SR-141716A/WIN55,212-2 and immediately returned. Motor activity was initiated 10 min following the second administration and recorded for 1 h, The low dose of WIN55,212-2 was chosen based on its stimulatory role in motor activity -an effect that is masked in non-habituated animals, whereas the high dose was selected based on its motor suppressant actions ). These two doses were also selected for the neurochemical experiments (see below) as representative of motor-stimulating and motor-suppressant doses of cannabinoid agonists.
Neurochemical studies : in vivo microdialysis
Rats (n=95) were anaesthetized with a ketamine (100 mg/kg)/xylazine (10 mg/kg) cocktail administered i.m. Atropine sulfate (0.6 mg/kg i.m.) was administered to reduce bronchial secretions. After securing the rat in the stereotaxic frame, the probe was implanted unilaterally in the striatum, NAc or PFC [membrane length : 2, 2, 4 mm, respectively ; coordinates : anterior-posterior (AP) : +0.48, mediolateral (ML) : +3.0, dorsoventral (DV) : x5.0 ; AP : +1.6, ML : +1.4, DV : x6.3 ; AP : +3.2, ML : +0.6, DV : x2.0, respectively], according to Paxinos & Watson (1998) (Fig. 1) .
The microdialysis probes were produced in house as follows. A fused silica capillary tube was inserted through the inner bore of a 23 gauge stainless steel tube to extend 3 mm beyond its tip. The dialysis membrane (diameter 210 mm) was fitted over the fused silica tube and glued to the tip of the stainless-steel tubing with epoxy glue. The length of the membrane was cut and the tip of the membrane plugged with epoxy glue. The active dialyzing surface was varied according to the implantation region. Inflow of the perfusion fluid was through the stainless steel tube and the outflow was via the fused silica capillary tubing.
The probe was secured to the skull by three stainless steel anchor screws and rapid-setting acrylic dental cement, which surrounded the assembly. The probe was then connected to the microdialysis pump through a liquid swivel (CMA-120, system for freely moving animals ; Canergie Medicin AB, Sweden) and was perfused with a modified Ringer's solution (147 mM NaCl, 3 mM KCl, 1.3 mM CaCl 2 . 2H 2 O, 1 mM MgCl 2 . 6H 2 O ; pH 7.4) at a flow rate of 0.5 ml/min while the animal recovered for a 24 h period.
On the day of the experiment, the Ringer's solution was perfused at a rate of 1 ml/min. Samples were collected every 30 min (CMA microfraction collector) into microcentrifuge tubes containing 5 ml 0.2 N perchloric acid (Merck KgaA, Germany) to avoid dopamine degradation. Animals were allowed a 2 h stabilization period, before three baseline samples were collected. During the fourth sampling, drug was administered (i.p.) to the rats, according to designated treatment group (n=5-6 rats/region) : vehicle/vehicle, vehicle/WIN55,212-2 (0.1, 1 mg/kg), SR-141716A (0.03 mg/kg)/vehicle and SR-141716A/WIN 55,212-2, with 10 min interval between injections. Ten samples were collected in total from each experimental animal. Immediately after collection, the sample was divided and stored (x80 xC) for subsequent dopamine and glutamate analysis. The proper location of the probe was verified histologically at the end of the experiment.
Dopamine assay
Samples were injected into a high-performance liquid chromatography (HPLC) system (BAS-LC4B ; Bioanalytical Systems Inc., USA) equipped with an electrochemical detector. The working electrode of the electrochemical detector was set at +0.8 mV. A Hypersil, Elite C18, 50 mmr1 mm, 5 mm particle size (Thermo Electron, UK) column was used and the mobile phase consisted of an acetonitrile (Merck KgaA, Germany), 50 mM phosphate buffer (10 : 90 dilution), pH 3.0, containing 300 mg/l 5-octylsulfate sodium salt (Merck KgaA) as the ion-pair reagent and 20 mg/l Na 2 EDTA (Reidel-de Haen AG, Germany). The detection limit for dopamine in the assay was 1 pg/20 ml (injection volume).
Glutamate assay
Glutamate measurements were performed using a Pharmacia LKB 2248 HPLC pump coupled with a BAS-LC4B electrochemical detector. Pre-column derivatization was conducted as described previously (Kokras et al. 2009) , with minor modifications. In brief, 10 ml of each sample (standard solution or microdialysis sample) was added to microfuge tubes together with 10 ml 0.1 M, pH 9.6 Borax buffer (SigmaAldrich, USA) and 1 ml derivatizing reagent, orthophthaldialdehyde (Sigma-Aldrich), left at room temperature to react for 10 min and then injected. The working electrode was glassy carbon, the reference electrode was Ag/AgCl and the columns used were Hypersil ODS, 250 mmr4.6 mm, 5 mm particle size (Thermo Electron, UK). The mobile phase consisted of an acetonitrile (Merck, Germany)-100 mM phosphate buffer (5 : 95 dilution), pH 4.9, containing 50 mM Na 2 EDTA (Riedel-de Haën, Germany). The limit of detection was 1 pg/27 ml (injection volume).
Drugs
WIN55,212-2 (Tocris Bioscience, UK) was dissolved in a vehicle solution that consisted of 5 % dimethylsulfoxide, 5 % cremophor EL and 90 % NaCl (0.9 %). SR-141716A was purchased from a local pharmacy (Acomplia 20 mg/tab ; Sanofi-Aventis) and was appropriately dissolved in a vehicle solution that consisted of 5 % dimethylsulfoxide, 5 % cremophor EL and 90 % NaCl (0.9 %).
Statistical analysis
All behavioural data were analysed using one-way analysis of variance (ANOVA) with treatment as factor followed by LSD post-hoc tests.
The average of the first three in vivo dialysis samples was taken as the basal value and was defined as 100 %. All subsequent samples were expressed as the percentage of basal levels. Statistical analysis was performed using repeated measures ANOVA with treatment as the between-subjects factor and time as the within-subjects factor. Subsequent repeated measures ANOVA and one-way ANOVAs were performed, when appropriate, for purposes of comparisons between specific groups.
All analyses were performed with SPSS 16.0 (SPSS Inc., USA). A p<0.05 value was considered statistically significant.
Results
Behavioural studies
One-way ANOVA revealed a reduction in ambulatory distance and vertical counts following administration of 1 mg/kg WIN55,212-2 in non-habituated rats, which was reversed by co-administration of SR-141716A [0.03 mg/kg ; F 3,40 =3.69, 3.21, p=0.033, p=0.043, respectively (Fig. 2 a) ].
An increase in ambulatory distance and vertical counts was observed following administration of 0.1 mg/kg WIN55,212-2 in habituated rats, which was reversed by co-administration of SR-141716A [0.03 mg/kg ; F 3,40 =4.69, 3.21, p=0.013, p=0.036, respectively (Fig. 2 b) ]. Administration of SR-141716A did not modify motor activity in either non-habituated or habituated rats. 
Neurochemical studies
Dopamine release in the striatum
A significant treatment effect (F 2,14 =2.836, p=0.05) and differences between basal dopamine and dopamine levels at time-points 30, 60, 90 and 120 min (F 1,14 =5.68, 4.91, 6.31, 5.34, p=0.032, 0.044, 0.025, 0.037, respectively) were found following repeated measures ANOVA. Subsequent analyses per treatment group revealed increased dopamine release at time-points (min) 30, 60 and 90 after administration of both doses of WIN55,212-2 [0.1, 1 mg/kg ; F 1,4 =12. 24, 9.56, 24.34, p=0.025, 0.037, 0.009 ; F 1,7 =6.80, 6.36, 4.76, p=0.035, 0.04, 0.05, respectively (Fig. 3 a) ].
Separate one-way analyses at each time-point revealed statistically significant effects between WIN55,212-2 (0.1, 1 mg/kg) and co-administration of SR-141716A (0.03 mg/kg) and respective doses of WIN55,212-2 at time-points 30, 60 and 90 min (F 5,27 =2.98, 3.20, 3.01, p=0.049, 0.037, 0.045, respectively) , thus indicating antagonism of the WIN55,212-2-induced increase in dopamine release (Fig. 3 a) . Administration of SR-141716A (0.03 mg/kg) yielded no change in dopamine levels compared to basal dopamine. (Fig. 3 b) ]. Separate one-way analyses at each time-point revealed statistical significance at time-points 30 and 60 min (F 5,30 =3.22, 3.81, p=0.033, 0.011, respectively) with differences between WIN55,212-2 and coadministration of SR-141716A (0.03 mg/kg) and WIN55,212-2, thus indicating reversal of the WIN55,212-2-induced decrease in glutamate release (Fig. 3 b) . Administration of SR-141716A (0.03 mg/kg) yielded no change in glutamate levels compared to basal glutamate.
Glutamate release in the striatum
Dopamine release in the NAc
A two-way repeated measures ANOVA revealed differences between basal levels and dopamine at timepoints : 30, 60, 90, 120 and 150 min (F 1,11 =5.83, 9.22, 7.23, 5.89, 5.17, p=0.042, 0.016, 0.028, 0.041, 0.053, respectively) as well as a significant interaction (timepointsrtreatment) at time-point 60 min (F 2,11 =4.55, p=0.048). Separate repeated measures ANOVAs per treatment group showed increased dopamine levels at time-points 60 and 90 min after administration of the higher dose of WIN55,212-2 (1 mg/kg ; F 1,5 =9.90, 10.51, p=0.05, 0.023, respectively (Fig. 3 c) ]. The low dose of WIN55,212-2 (0.1 mg/kg) induced a delayed increase in dopamine release without showing statistical significance.
Separate one-way analyses at each time-point revealed statistically significant effects between WIN55,212-2 (1 mg/kg) and vehicle as well as WIN55,212-2 (1 mg/kg) and co-administration of SR-141716A (0.03 mg/kg) and WIN55,212-2 (1 mg/kg) at time-points 60 and 90 (min ; F 3,17 =14.05, 6.99, p=0.001, 0.013, respectively), thus indicating antagonism of the WIN55,212-2-induced increase in dopamine release (Fig. 3 c) . Administration of SR-141716A (0.03 mg/kg) yielded no change in dopamine levels compared to basal dopamine (Fig. 3 c) .
Glutamate release in the NAc
A two-way repeated ANOVA measure revealed a significant treatment effect (F 2,12 =5.326, p=0.024), differences between basal levels and glutamate at time-points : 90, 120, 150, 180 and 210 min (F 1,12 =25. (Fig. 3 d) ].
Separate one-way analyses at each time-point revealed a statistical significance at time-points 90, 120, 150 and 180 min (F 5,23 =3.85, 5.46, 5.46, 3.24, p=0.019, 0.004, 0.004, 0.033, respectively) with differences between WIN55,212-2 and co-administration of SR-141716A (0.03 mg/kg) and respective doses of WIN55,212-2, thus indicating reversal of the WIN55,212-2-induced decrease in glutamate release (Fig. 3 d) . Administration of SR-141716A (0.03 mg/kg) yielded no change in glutamate levels compared to basal glutamate.
Dopamine release in the PFC
Repeated measures ANOVA revealed a treatment effect (F 2,14 =4.128, p=0.05). Separate analysis revealed an increase in dopamine release at the first two timepoints (30 and 60 min) after a high dose of WIN55,212-2 (1 mg/kg) administration (F 1,5 =6.309, 25.691, p=0.05, 0.007).
SR-141716A administration (0.03 mg/kg) on its own had no effect on dopamine release, whereas coadministration with WIN55,212-2 (1 mg/kg) reversed WIN55,212-2-induced dopamine release as deduced from LSD post-hoc analysis, indicating a statistically significant difference at the 30 and 60 min time-points between these two groups [F 4,17 =3.82, 4.13, p=0.026, 0.023, respectively (Fig. 3 e) ].
Glutamate release in the PFC
A two-way repeated ANOVA measures revealed a significant treatment effect (F 2,12 =13.78, p=0.003), differences between basal levels and glutamate at time-points : 30, 60, 90, 120, 150, 180 and 210 min (F 1,12 =67.66, 47.73, 15.67, 16.17, 7.75, 28.32, 41.18, p<0.001, 0.001, p=0.003, 0.003, 0.021, p<0.001, 0.001, respectively) , as well as a significant interaction (timepointsrtreatment) at time-points 30, 60, 90, 120, 180 and 210 min (F 2,12 =26.64, 41.54, 6.31, 6.89, 11.22, 11.97, p<0.001, 0.001, p=0.019, 0.015, 0.004, 0.003, respectively) . Separate repeated measures ANOVAs per treatment group showed increased glutamate levels at time-points 30, 60, 90 and 120 min after administration of a high dose of WIN55,212-2 [1 mg/kg ; F 1,4 =47. 98, 45.23, 11.84, 7.57, p<0.001, 0.001, p=0 .003, 0.05, respectively (Fig. 3f)] .
Separate one-way analyses at each time-point revealed statistically significant differences at timepoints 30, 60, 90 and 120 min (F 3,15 =13.12, 4.22, 4.70, 4.63, p=0.001, 0.023, 0.019, 0.029, respectively) with differences between WIN55,212-2 (1 mg/kg) and coadministration of SR-141716A (0.03 mg/kg) and WIN55,212-2 (1 mg/kg), thus indicating reversal of the WIN55,212-2-induced decrease in glutamate release (Fig. 3 f) . Administration of SR-141716A (0.03 mg/kg) yielded no change in glutamate levels compared to basal glutamate.
Discussion
The present results show that WIN55,212-2 increased extracellular dopamine and inhibited glutamate release in the subcortical regions of the limbic (NAc) and basal ganglia circuitry (striatum) while, in the PFC, it increased both dopamine and glutamate release. Additionally, motor activity was biphasically modulated by WIN55,212-2, an effect that was not paralleled by dopaminergic or glutamatergic alterations observed in the subcortical and cortical regions tested. Both behavioural and neurochemical effects were counteracted with pre-administration of the CB 1 receptor antagonist, SR-141716A.
In line with our previous findings, WIN55,212-2 modified motor activity biphasically (Polissidis et al. 2010) . Specifically, a low dose (0.1 mg/kg) WIN55,212-2 stimulated locomotor activity and a high dose of WIN55,212-2 (1 mg/kg) decreased locomotor activity. These results are in agreement with several studies that addressed the modulatory role of cannabinoids on motor activity (Davis & Borgen, 1974 ; Drews et al. 2005 ; Rodvelt et al. 2007 ; Sanudo-Pena et al. 2000 ; Sulcova et al. 1998) .
Increased extracellular dopamine in the NAc and striatum following acute WIN55,212-2 administration reflects the effects of exogenous cannabinoids on dopamine neurotransmission. Our results are in line with previous in vivo studies that have shown dosedependent increases in dopamine efflux in the striatum following administration of D 9 -THC (Malone & Taylor, 1999) . Increases in extracellular dopamine release in the NAc have also been reported after D 9 -THC and WIN55,212-2 administration (Chen et al. 1990b ; Fadda et al. 2006 ; Lecca et al. 2006 ; Ng Cheong Ton et al. 1988 ; Tanda et al. 1997) . According to our previous data, both D 9 -THC and WIN55,212-2 stimulate dopamine biosynthesis in these brain regions (Polissidis et al. , 2010 . The low dose of WIN55,212-2 tested was unable to increase accumbal dopamine, although there was a tendency at later time-points. Perhaps a distinction should be made between the role of exogenous cannabinoids on dopamine function in striatal vs. limbic structures. However, the lack of differentiation between the shell and the core of the NAc regarding probe implantation could also contribute to low dose WIN55,212-2's lack of effect as dopamine release corresponds to the shell, exclusively (Tanda et al. 1997) .
A transient and moderate increase in extracellular dopamine was found in the PFC following acute WIN55,212-2 administration. The present results are in line with previous findings that have shown dosedependent increases in dopamine efflux in the PFC following D 9 -THC administration (Chen et al. 1990a ; Pistis et al. 2002) . In support of these results, our previous findings have shown that both D 9 -THC and WIN55,212-2 stimulate dopamine biosynthesis in the PFC (Polissidis et al. , 2010 ; an effect that was also observed by Jentsch et al. (1997) after D 9 -THC administration. Both D 9 -THC and WIN55,212-2 have been observed to stimulate mesoprefrontal dopaminergic neurotransmission and, in both cases, SR-141716A effectively reversed this result (Diana et al. 1998) . It should be mentioned that systemic administration of WIN55,212-2 induced a lower in magnitude increase in the cortical dopamine release as compared to that observed in the striatum while the low dose did not affect dopamine release. According to our results, WIN55,212-2 affects dopaminergic neurotransmission in the striatum to a greater extent than in the NAc, two subcortical regions that are involved in the expression of motor activity as well as motivation and reward processes. In addition, higher doses of WIN55,212-2 affected cortical dopamine function. This effect may be related to a negative impact of cannabinoids on cognitive and executive functioning through the over-activation of dopaminergic transmission in the PFC (Diana et al. 1998 ; Kuepper et al. 2010 ; Solinas et al. 2008) . In general, converging effects on extracellular dopamine release following administration of an exogenous CB 1 agonist were observed in both the cortical and subcortical regions.
The effects of systemic administration of WIN55,212-2 on dopamine release were fully reversed by a low dose of SR-141716A pre-treatment. Similar to previous results, low doses of SR-141716A did not have an effect on cortical extracellular dopamine levels (Tzavara et al. 2003) . In line with previous findings, our results further support the role of CB 1 receptor stimulation on the modulation of dopamine release (Pistis et al. 2002 ; Tanda et al. 1997) . Cannabinoids may alter dopamine neurotransmission and dopamine-related behaviours via an indirect action on caminobutyric acid (GABA)-and glutamate-containing neurons. These neurons are abundant in CB 1 receptors and may in turn modify dopamine neurotransmission via pre-synaptic or post-synaptic mechanisms in the respective synapses (Fernandez-Ruiz et al. 2010 ; Laviolette & Grace, 2006) . Evidence also suggests a presence of CB 1 receptors on dopaminergic neurons in the ventral tegmental area, which opens the possibility of a direct action of cannabinoids on corticolimbic areas such as the NAc and PFC (Wenger et al. 2003) . However, an additional direct mechanism through the stimulation of vanilloid receptors located on dopaminergic neurons in the basal ganglia circuitry, especially with higher doses of WIN55,212-2 (Campos & Guimaraes, 2009) , may also contribute to the role of cannabinoids on dopamine function (Fernandez-Ruiz et al. 2010 ; Mezey et al. 2000 ; Starowicz et al. 2007) . A recent study confers an inhibitory role of central CB 2 receptors in locomotor activity as well as dopamine release. Thus, considering that WIN 55,212-2 possesses a degree of affinity for the CB 2 receptor, the possibility of underlying CB 2 effects must not be overlooked (Xi et al. 2011) . The lack of effect of a low dose of WIN55,212-2 on dopamine release in the NAc and PFC could be a consequence of possible competing CB 1 and CB 2 receptor function that may be superseded by CB 1 receptors at higher doses. Overall, the findings support exogenous cannabinoid-mediated facilitation of corticolimbic and striatal dopamine neurotransmission via direct and indirect mechanisms.
Interestingly, glutamate was decreased in the NAc and striatum after WIN55,212-2 administration, findings supported by previous electrophysiological studies (Gerdeman & Lovinger, 2001 ; Robbe et al. 2001) . Inhibitory effects of cannabinoid treatment have been observed in the cerebellum, hippocampus, amygdala and substantia nigra (Azad et al. 2003 ; Levenes et al. 1998 ; Piomelli, 2008 ; Shen et al. 1996 ; Szabo et al. 2000) . It should be mentioned that the decrease in striatal glutamate release was mostly observed following the higher dose. The present findings are in line with our previous results (Galanopoulos et al. 2011) indicating decreased glutamatergic function in the NAc, especially following the higher dose of WIN55,212-2, in high responder rats. On the other hand, WIN55,212-2 administration induced an increase in extracellular glutamate efflux in the PFC. In support of these findings, Pistis et al. (2002) confirm these data showing increased glutamate in the PFC after D 9 -THC administration in anaesthetized rats. Glutamate was also increased after both high and low doses of WIN55,212-2 in the PFC (Ferraro et al. 2001) . Increased glutamate in the PFC upon cannabinoid administration may be due to direct stimulation of recurrent axon collaterals of pyramidal neurons or to the potentiation of glutamate inputs from adjacent cortical or subcortical areas (Pistis et al. 2002) . One study exclusively observed depressed glutamatergic excitatory post-synaptic currents in PFC slices upon administration of WIN55,212-2 and CP-55940 ; however, this discrepancy may be accounted for by methodological differences (Auclair et al. 2000) . Glutamate tissue levels were increased in the PFC following a high dose WIN55,212-2 administration (Galanopoulos et al. 2011) . This result, together with the increase in extracellular glutamate concentration observed in this study, demonstrates the potentiation of glutamate extracellular and intracellular efflux following WIN55,212-2 administration. WIN55,212-2-induced effects in the PFC were reversed by a low dose of SR-141716A, findings also reported by Ferraro et al. (2001) . Based on these results and the aforementioned studies, WIN55,212-2 appears to modulate glutamate release bidirectionally when comparing cortical and subcortical tissues and this modulation is CB 1 dependent.
In general, our behavioural results showed that high doses of cannabinoids induce an impairment in the expression of novelty-induced behaviour, while low doses disrupt behavioural habituation, resulting in increased motor and exploratory activity. Our neurochemical findings demonstrate that cannabinoid treatment exerts excitatory effects on dopamine release and both excitatory and inhibitory effects on glutamate neurotransmission, depending upon the brain region, and these effects are more robust following the higher dose of WIN55,212-2. In particular, striatal dopamine release was increased while glutamate release was decreased, findings that support the role of cannabinoids in physiological and pathological conditions related to basal ganglia activity. Interestingly, the increase in dopamine and decrease in glutamate efflux in the NAc, together with the parallel increase in cortical dopamine and glutamate release, indicates the interaction between cannabinoids and key neurotransmitters in corticolimbic structures involved in the pathogenesis of schizophrenia and drug abuse. The fact that there is no consistent correlation between the biphasic behavioural effects and the respective dopamine and glutamate alterations induced by WIN55,212-2 should be addressed. In particular, although a high dose of WIN55,212-2 produces hypolocomotion, it increases dopamine release and decreases glutamate levels in both the striatum and NAc, whereas the hyperactivity following a low dose of WIN55,212-2 is accompanied by increased striatal dopamine release and glutamate release in the PFC, together with reduction of glutamate levels in the striatum and NAc. This lack of coincidence between behavioural and neurochemical responses following WIN55,212-2 administration is most likely accounted for by the critical region-dependent regulation of cortical and subcortical release of both dopamine and glutamate and especially the dissociable effects on glutamate release, In addition, the possibility of competing CB 2 receptor-mediated effects by WIN55,212-2 cannot be dismissed. This study confirms and extends previous findings focused on the effect of exogenous cannabinoids of specific doses on motoric effects and on dopamine and glutamate neurotransmission, simultaneously. The over-activity, suppression or dysregulation of these specific neurotransmitters in basal ganglia or corticolimbic structures have been associated with basal ganglia disorders, drug addiction and related psychoses. Thus, the behavioural and neurochemical effects of cannabinoids in these distinct brain regions is of great importance for furthering our understanding of specific central nervous system disorders and their pathophysiology, as well as for approaching new therapeutic strategies.
